To include your compound in the COVID-19 Resource Center, submit it here.

FDA releases Iressa documents

Approval of AstraZeneca's application for accelerated approval of its Iressa to treat non-small cell lung cancer (NSCLC) is likely to hinge on the company's ability to convince an advisory panel to disregard data from two trials of the compound in combination

Read the full 419 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE